Development of proteasome inhibitors in oncology and autoimmune diseases.

@article{Bennett2008DevelopmentOP,
  title={Development of proteasome inhibitors in oncology and autoimmune diseases.},
  author={Mark K. Bennett and Christopher J. Kirk},
  journal={Current opinion in drug discovery & development},
  year={2008},
  volume={11 5},
  pages={616-25}
}
The proteasome is a multicatalytic protease complex that mediates the controlled degradation of intracellular proteins, including key components of pathways that contribute to cancer cell growth and immune cell signaling. Validation for the proteasome as a therapeutic target in oncology was provided by bortezomib, a proteasome inhibitor that was approved for the treatment of multiple myeloma in 2003. Since that time, a number of structurally and mechanistically distinct proteasome inhibitors… CONTINUE READING